These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

909 related articles for article (PubMed ID: 20872215)

  • 21. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
    Cremers S; Garnero P
    Drugs; 2006; 66(16):2031-58. PubMed ID: 17112299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing.
    Habermann B; Kafchitsas K; Olender G; Augat P; Kurth A
    Calcif Tissue Int; 2010 Jan; 86(1):82-9. PubMed ID: 19960189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis.
    O'Connell MB
    J Manag Care Pharm; 2006 Jul; 12(6 Suppl A):S10-9; quiz S26-8. PubMed ID: 17269853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone biology, signaling pathways, and therapeutic targets for osteoporosis.
    Iñiguez-Ariza NM; Clarke BL
    Maturitas; 2015 Oct; 82(2):245-55. PubMed ID: 26255682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of combination therapy in the treatment of postmenopausal osteoporosis.
    Compston J
    Endocrine; 2012 Feb; 41(1):11-8. PubMed ID: 22038453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2008 Oct; 18(10):1483-92. PubMed ID: 18830046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
    Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
    Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
    Leder BZ; Tsai JN; Jiang LA; Lee H
    Bone; 2017 May; 98():54-58. PubMed ID: 28286299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
    Dempster DW; Zhou H; Recker RR; Brown JP; Recknor CP; Lewiecki EM; Miller PD; Rao SD; Kendler DL; Lindsay R; Krege JH; Alam J; Taylor KA; Janos B; Ruff VA
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1353-63. PubMed ID: 26859106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
    Bilezikian JP
    Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological management of osteogenesis.
    Nardone V; D'Asta F; Brandi ML
    Clinics (Sao Paulo); 2014 Jun; 69(6):438-46. PubMed ID: 24964310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates.
    Sousa IO; Diniz ET; Marques TF; Griz L; Coutinho Mde A; Bandeira F
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):244-9. PubMed ID: 20485916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.